Assessment of hormone refractory prostate cancer
Data up to Jan 2025
Total Citations Per Year
Abstract
References (15)
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
1993 • 417 citations
MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS
1995 • 234 citations
Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial
1993 • 133 citations
Clinical Trials in Relapsed Prostate Cancer: Defining the Target
1996 • 129 citations
Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate Cancer
1996 • 97 citations
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853
1993 • 86 citations
Quality of life after palliative radiotherapy in patients with hormone‐resistant prostate cancer: single institution experience
1994 • 35 citations
Hormone refractory disease
1995 • 33 citations
Use of Intravenous Stilbestrol Diphosphate in Patients with Prostatic Carcinoma Refractory to Conventional Hormonal Manipulation
1991 • 27 citations
High-Dose Medroxyprogesterone Acetate versus Prednisolone in Hormone-Resistant Prostatic Cancer
1985 • 19 citations
Androgens, Antiandrogens and Androgen Receptor Abnormalities
1996 • 19 citations
Chemotherapy for endocrine resistant cancer of the prostate.
1990 • 12 citations
Parameters of response and progression in prostate cancer.
1990 • 5 citations
Objective response criteria in phase II and phase III studies.
1988 • 5 citations
Scientific background of hormonal treatment of prostate cancer.
1990 • 3 citations